Tango Therapeutics Inc. vs Zscaler Inc — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Zscaler Inc trades at $217.11 (market cap $36.81B). The key difference: Zscaler Inc is far larger — about 9.8× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Zscaler Inc for 41 Days on average.
| TNGX | ZS | |
|---|---|---|
Market Cap | $3.75B | $36.81B |
Volume | 9,619,106 | 2,661,492 |
Sector | Health | Technology |
52-Week High | $32.90 | $336.27 |
52-Week Low | $7.50 | $118.05 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $2.77B | $35.20B |
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Zscaler (ZS) trades at $220.79, down 2.21% on the day, amid mixed signals. The stock shows strong technical momentum with bullish moving averages, but RSI suggests potential overbought conditions. Fundamentally, revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net income margin of -1.88%. Recent news includes executive changes and an upcoming Investor Day on October 6, 2026.
The outlook is cautiously optimistic. Analyst consensus is strongly bullish with a $222.83 price target, but risks include persistent losses, competitive pressures, and insider selling. Upside hinges on AI-driven bookings growth and execution stability post-CRO transition. Investors should weigh high valuation multiples against the company's growth trajectory and market position in cybersecurity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →